Recent advances in the discovery and development of anti-influenza drugs

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 8, 2004, Pages 1153-1168

  Klumpp, Klaus ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Antiviral agents; Antiviral therapy; Influenza prophylaxis; Neuraminidase; Nuclease inhibition; RNA polymerase inhibition

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; A 315675; ABT 675; ALPHA GLUCOSIDASE INHIBITOR; ANTIVIRUS AGENT; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; CYCLOPENTANE DERIVATIVE; ENDONUCLEASE; ENZYME INHIBITOR; INFLUENZA VACCINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OSELTAMIVIR; PERAMIVIR; PYRAZINE DERIVATIVE; R 125489; RIBAVIRIN; RNA; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

AEROSOL; ANTIGENICITY; ANTIVIRAL ACTIVITY; ASIA; ASTHENIA; BIRD DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; EUROPE; GENETIC REASSORTMENT; GENETIC VARIABILITY; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LIVER DYSFUNCTION; MOUSE; NAUSEA; NONHUMAN; NORTH AMERICA; PREDICTION; RECURRENT INFECTION; REVIEW; RNA REPLICATION; TREATMENT FAILURE; VIRUS MORPHOLOGY; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 4344664616     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.8.1153     Document Type: Review

References (77)

1. COX NJ, SUBBARAO K: Global epidemiology of influenza: past and present. Ann. Rev. Med. (2000) 51:407-421.
2. SULLIVAN KM: Health impact of influenza in the United States. Pharmacoeconomics (1996) 9:26-33.
3. SKOWRONSKI D, KING A, TAM T et al.: Update: influenza activity - United States, 2003-04 Season. MMWR (2004) 53:284-287.
4. BRIDGES CB, HARPER SA, FUKUDA K, UYEKI TM, COX NJ, SINGLETON JA: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR (2003) 52(RR08):1-36.
5. SIMONSEN L, FUKUDA K, SCHONBERGER LB, COX NJ: The impact of influenza epidemics on hospitalizations. J. Infect. Dis. (2000) 181:831-837.
6. SHUI I, BHAT N, GLOVER M, POSEY D: Update: influenza-associated deaths reported among children aged < 18 years - United States, 2003-04 influenza season. MMWR (2004) 52(53):1286-1288.
7. WRIGHT PF, WEBSTER RG: Orthomyxoviruses. In: Fields Virology. Knipe DM Howley PM (Eds), Lippincott Williams & Wilkins, Philadelphia. (2001) 1:1533-1580.
8. FOUCHIER RA, SCHNEEBERGER PM, ROZENDAAL FW et al.: Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. US4 (2004) 101:1356-1361.
9. STEVENS J, CORPER AL, BASLER CF, TAUBENBERGER JK, PALESE P, WILSON IA: Structure of the uncleaved human H hemagglutinin from the extinct 1918 influenza virus. Science (2004) 303:1866-1870.
10. WANG T: Recent advances in the discovery and development of anti-influenza drugs. Expert Opin. Ther. Patents (2002) 12:845-861.
11. HAYDEN FG, OSTERHAUS AD, TREANOR JJ et al.: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG 167 Influenza Study Group. N. Engl. J. Med. (1997) 337:874-880.
12. SILAGY CA, CAMPION K. Effectiveness and role of zanamivir in the treatment of influenza infection. Ann. Med. (1999) 31:313-317.
13. MONTO AS, FLEMING DM, HENRY D et al.: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis. (1999) 180:254-261.
14. TREANOR JJ, HAYDEN FG, VROOMAN PS et al.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial: US Oral Neuraminidase Study Group. JAMA (2000) 283:1016-1024.
15. NICHOLSON KG, AOKI FY OSTERHAUS AD et al.: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 355:1845-1850.
16. SINGH S, BARGHOORN J, BAGDONAS A et al.: Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin. Drug Invest. (2003) 23:561-569.
17. GOVORKOVA EA, LENEVA IA, GOLOUBEVA OG, BUSH K, WEBSTER RG: Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. (2001) 45:2723-2732.
18. LENEVA IA, ROBERTS N, GOVORKOVA EA, GOLOUBEVA OG, WEBSTER RG: The neuraminidase inhibitor GS-4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N 1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. (2000) 48:101-115.
19. GUBAREVA LV, PENN CR, WEBSTER RG: Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology (1995) 212:323-330.
20. PEGG MS, VON ITZSTEIN M: Slow-binding inhibition of sialidase from influenza virus. Biochem. Mol. Biol. Int. (1994) 32:851-858.
21. KATI WM, SALDIVAR AS, MOHAMADI F, SHAM HL, LAVER WG, KOHLBRENNER WE: GS-4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains. Biochem. Biophys. Res. Commun. (1998) 244:408-413.
22. KIM CU, LEW W, WILLIAMS MA et al.: Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. (1997) 119:681-690.
23. LEW W, CHEN X, KIM CU: Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. (2000) 7:663-672.
24. BABU YS, CHAND P, BANTIA S et al.: BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. (2000) 43:3482-3486.
25. SIDWELL RW, SMEE DF: Peramivir (BCX-18-12, RWJ-270201): potential new therapy for influenza. Expert Opin. Investig. Drugs (2002) 11:859-869.
26. KATI WM, MONTGOMERY D, CARRICK R et al.: In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. (2002) 46:1014-1021.
27. HONDA T, MASUDA T, YOSHIDA S, ARAI M, KOBAYASHI Y, YAMASHITA M: Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives. Bioorg. Med. Chem. Lett. (2002) 12:1921-1924.
28. YAMASHITA M, OHNO A, TOMOZAWA T, YOSHIDA S: R-118958, a unique anti-influenza agent: a prodrug form of R- 125489, a novel inhibitor of influenza virus neuraminidase. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA. Sep 14-17 (2003) Poster F-1829.
29. NAKAI N, OITATE M, HOSHI M, KOBAYASHI N, YAMAMURA N, HIROTA T: R118958, a unique anti-influenza agent: pharmacokinetics and metabolism after intranasal/intratracheal administration to rats and mice. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA. Sep 14-17 (2003) Poster F-1833.
30. YAMASHITA M, OHNO A, TOMOZAWA T, YOSHIDA S: R-118958, a unique anti-influenza agent: single administration shows high efficacy for both prophylaxis and treatment. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, Sep 14-17 (2003) Poster F-1830.
31. RENNECKE J, HIROTA T, PUCHLER K: R-118958, a unique anti-influenza agent: safety, tolerability and pharmacokinetics in healthy male volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA. Sep 14-17 (2003) Poster F-1834.
32. PATTON JS: Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. (1996) 19:3-36.
33. BYRON PR, PATTON JS: Drug delivery via the respiratory tract. J. Aerosol. Med. (1994) 7:49-75.
34. HONDA T, YOSHIDA S, ARAI M, MASUDA T, YAMASHITA M: Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Bioorg. Med. Chem. Lett. (2002) 12:1929-1932.
35. MASUDA T, YOSHIDA S, ARAI M, KANEKO S, YAMASHITA M, HONDA T: Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Chem. Pharm. Bull. (Tokyo) (2003) 51:1386-1398.
36. WATSON KG, CAMERON R, FENTON RJ et al.: Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorg. Med. Chem. Lett. (2004) 14:1589-1592.
37. DIGGORY P, FERNANDEZ C, HUMPHREY A, JONES V, MURPHY M: Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. Br. Med. J. (2001) 322:577-579.
38. MASUDA T, SHIBUYA S, ARAI M et al.: Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorg. Med. Chem. Lett. (2003) 13:669-673.
39. LAMB RA, KRUG RM: Orthomyxoviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds), Lippincott Williams & Wilkins. Philadelphia (2001):1487-1532.
40. DOAN L, HANDA B, ROBERTS NA, KLUMPP K: Metal ion catalysis of RNA cleavage by the influenza virus endonuclease. Biochemistry (1999) 38:5612-5619.
41. LEE MT, KLUMPP K, DIGARD P, TILEY L: Activation of influenza virus RNA polymerase by the 5′ and 3′ terminal duplex of genomic RNA. Nucleic Acids Res. (2003) 31:1624-1632.
42. PARKES KE, ERMERT P, FASSLER J et al.: Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J. Med. Chem. (2003) 46:1153-1164.
43. TOMASSINI J, SELNICK H, DAVIES ME et al.: Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob. Agents Chemother. (1994) 38:2827-2837.
44. HASTINGS JC, SELNICK H: WOLANSKI B, TOMASSINI JE: Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob. Agents Chemother. (1996) 40:1304-1307.
45. SINGH SB, TOMASSINI JE: Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonudease inhibitors of influenza virus. J. Org. Chem. (2001) 66:5504-5516.
46. TOMASSINI JE, DAVIES ME, HASTINGS JC et al.: A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob. Agents Chemother. (1996) 40:1189-1193.
47. KLUMPP K, HANG JQ, RAJENDRAN S et al.: Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res. (2003) 31:6852-6859.
48. CHUNG TD, CIANCI C, HAGEN M et al.: Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. Proc. Natl. Acad. Sci. USA (1994) 91:2372-2376.
49. CIANCI C, COLONNO RJ, KRYSTAL M: Differential effect of modified capped RNA substrates on influenza virus transcription. Virus Res. (1997) 50:65-75.
50. KLUMPP K, DOAN L, ROBERTS NA, HANDA B: RNA and DNA hydrolysis are catalyzed by the influenza virus endonuclease. J. Biol. Chem. (2000) 275:6181-6188.
51. TADO M, ABE T, HATTA T et al.: Inhibitory effect of modified 5′-capped short RNA fragments on influenza virus RNA polymerase gene expression. Antivir. Chem. Chemother. (2001) 12:353-358.
52. HOOKER L, SULLY R, HANDA ONO N, KOYANO H, KLUMPP K: Quantitative analysis of influenza virus RNP interaction with RNA cap structures and comparison to human cap binding protein eIF4E. Biochemistry (2003) 42:6234-6240.
53. YANG SH, SHARROCKS AD, WHITMARSH AJ: Transcriptional regulation by the MAP kinase signaling cascades. Gene (2003) 320:3-21.
54. PLESCHKA S: WOLFF T EHRHARDT C et al.: Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. (2001) 3:301-305.
55. LUDWIG S, WOLFF T, EHRHARDT C et al.: MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. (2004) 561:37-43.
56. ALLEN LF, SEBOLT-LECIPOLD J, MEYER MB: C1-1040 (PD 184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol, (2003) 30:105-116.
57. FAVATA MF, HORIUCHI KY, MANOS EJ et al.: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. (1998) 273:18623-18632.
58. SEBOLT-LEOPOLD JS, DUDLEY DT HERRERA R et al.: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. (1999) 5:810-816.
59. SEGER R, AHN NG, POSADA J et al.: Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J. Biol. Chem. (1992) 267:14373-14381.
60. WITYAK J, HOBBS FW, GARDNER DS et al.: Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:1483-1486.
61. WATERHOUSE DM, RINEHART J, ADJEI AA, HECHT JR, NATALE RB, AL E: A Phase II study of an oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon or pancreatic cancer. 39th Annual Meeting of the American Society of Clinical Oncology. (2003) Abstracts 204 and 816.
62. MEHTA A, OUZOUNOV S, JORDAN R et al.: Imino sugars that are less toxic but more potent as antivirals, in vitro, compared with N-n-nonyl DNJ. Antivir. Chem. Chemother. (2002) 13:299-304.
63. JORDAN R, NIKOLAEVA OV, WANG L et al.: Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions. Virology (2002) 295:10-19.
64. BLOCK TM, JORDAN R: Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs. Antivir. Chem. Chemother. (2001) 12:317-325.
65. ROTH H, MCPHERSON M, HAMEDANI P, AL E: Phase I tolerance and pharmacokinetics of a new castanospermine derivative, MDL-28574A. 11th International Conference on AIDS (1996) Abstract 284.
66. FURUTA Y, TAKAHASHI K, FUKUDA Y et al.: In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. (2002) 46:977-981.
67. TAKAHASHI K, FURUTA Y, FUKUDA Y et al.: In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother. (2003) 14:235-241.
68. STREETER DG, MILLER JP, ROBINS RK, SIMON LN: The enzymic conversion of 1,2,4-triazole-3-carboxamide to ribavirin-5′ -phosphate and its relationship to the proposed mechanism of action. Ann. NY Acad. Sci. (1977) 284:201-210.
69. AOKI FY, MACLEOD MD, PAGGIARO P et al.: Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. (2003) 51:123-129.
70. TISDALE M, APPLEYARD G, TUTTLE J et al.: Inhibition of influenza A and B viruses by 2′-deoxy-2′-fluororibosides. Antiviral Chem. Chemother. (1993) 4:281-287.
71. TISDALE M, ELLIS M, KLUMPP K, COURT S, FORD M: Inhibition of Influenza virus transcription by 2′-deoxy-2′-fluoroguanosine. Antimicrob. Agents Chemother. (1995) 39: 2454-2458.
72. ROBERTS NA: Anti-influenza drugs and neuraminidase inhibitors. Prog. Drug Res. (2001) 56:195-237.
73. ROBERTS NA: Treatment of influenza with neuraminidase inhibitors: virological implications. Phil. Trans. R. Soc. Lond. B Biol. Sci. (2001) 356:1895-1897.
74. MCKIMM-BRESCHKIN J, TRIVEDI T, HAMPSON A et al.: Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. (2003) 47:2264-2272.
75. GUBAREVA LV, WEBSTER RG, HAYDEN FG: Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. (2001) 45:3403-3408.
76. TAYLOR DL, KANG MS, BRENNAN TM, BRIDGES CG, SUNKARA PS, TYMS AS: Inhibition of α-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL-28574) and its consequences in human immunodeficiency vinis-infected T cells. Antimicrob. Agents Chemother. (1994) 38:1780-1787.
77. HERLOCHER ML, CARR J, IVES J et al.: Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. (2002) 54:99-111.